Zobraziť v EDS

Ultrasound targeted microbubbles for theranostic applications in liver diseases: from molecular imaging to targeted therapy.

Uložené v:
Podrobná bibliografia
Názov: Ultrasound targeted microbubbles for theranostic applications in liver diseases: from molecular imaging to targeted therapy.
Autori: Zhang C; Department of Ultrasound Imaging, The First College of Clinical Medical Science, China Three Gorges University & Yichang Central People's Hospital, Yichang, China.; Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, China., Zhang Q; Department of Ultrasound Imaging, The First College of Clinical Medical Science, China Three Gorges University & Yichang Central People's Hospital, Yichang, China.; Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, China., Xu Q; Department of Ultrasound Imaging, The First College of Clinical Medical Science, China Three Gorges University & Yichang Central People's Hospital, Yichang, China.; Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, China., Jiang X; Department of Ultrasound Imaging, The First College of Clinical Medical Science, China Three Gorges University & Yichang Central People's Hospital, Yichang, China.; Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, China., Ma Y; Department of Ultrasound Imaging, The First College of Clinical Medical Science, China Three Gorges University & Yichang Central People's Hospital, Yichang, China., Liu C; Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, China.; Medical College of China three Gorges University, Yichang, China., Zhou C; Department of Ultrasound Imaging, The First College of Clinical Medical Science, China Three Gorges University & Yichang Central People's Hospital, Yichang, China., Liu R; Department of Ultrasound Imaging, The First College of Clinical Medical Science, China Three Gorges University & Yichang Central People's Hospital, Yichang, China., Zhao Y; Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, China.; Medical College of China three Gorges University, Yichang, China., Liu Y; Department of Ultrasound Imaging, The First College of Clinical Medical Science, China Three Gorges University & Yichang Central People's Hospital, Yichang, China.; Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, China.
Zdroj: Drug delivery [Drug Deliv] 2025 Dec; Vol. 32 (1), pp. 2541656. Date of Electronic Publication: 2025 Aug 07.
Spôsob vydávania: Journal Article; Review
Jazyk: English
Informácie o časopise: Publisher: Taylor & Francis Country of Publication: England NLM ID: 9417471 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1521-0464 (Electronic) Linking ISSN: 10717544 NLM ISO Abbreviation: Drug Deliv Subsets: MEDLINE
Imprint Name(s): Publication: 2015->: Abingdon, Oxford : Taylor & Francis
Original Publication: Orlando, FL : Academic Press, c1993-
Výrazy zo slovníka MeSH: Microbubbles* , Liver Diseases*/drug therapy , Liver Diseases*/diagnostic imaging , Liver Diseases*/therapy , Drug Delivery Systems*/methods , Theranostic Nanomedicine*/methods , Molecular Imaging*/methods, Humans ; Animals ; Contrast Media
Abstrakt: Liver diseases, particularly chronic conditions leading to cirrhosis and hepatocellular carcinoma, represent a major global health burden with high mortality rates, necessitating innovative diagnostic and therapeutic approaches. Ultrasound-targeted microbubble destruction (UTMD) technology has emerged as a promising theranostic platform, combining enhanced contrast imaging with targeted drug/gene delivery capabilities. When activated by ultrasound, these microbubbles exhibit unique biophysical behaviors that significantly improve drug penetration, tissue perfusion, and site-specific delivery. This review comprehensively examines recent advancements in UTMD-based strategies for liver disease management, including microbubble design and imaging-targeted functionalization, and mechanisms of ultrasound-enhanced drug delivery, especially emerging theranostic applications. We further discuss the underlying biophysical principles governing microbubble-ultrasound interactions and their translational potential, providing insights for developing next-generation precision medicine approaches for hepatic disorders.
References: Front Pharmacol. 2019 Dec 05;10:1447. (PMID: 31866865)
Methods Mol Biol. 2020;2059:191-205. (PMID: 31435922)
Acta Pharm Sin B. 2017 Jul;7(4):447-452. (PMID: 28752029)
Stem Cell Res Ther. 2018 Dec 29;9(1):356. (PMID: 30594241)
Adv Drug Deliv Rev. 2020;154-155:236-244. (PMID: 32659255)
J Ultrasound Med. 2019 Dec;38(12):3221-3228. (PMID: 31124171)
Mol Imaging Biol. 2022 Apr;24(2):333-340. (PMID: 34787812)
Biomaterials. 2023 Mar;294:122025. (PMID: 36716588)
Biochem Pharmacol. 2022 Oct;204:115231. (PMID: 35988734)
ACS Appl Mater Interfaces. 2022 Jun 8;14(22):25197-25208. (PMID: 35615986)
Nanomedicine. 2022 Nov;46:102611. (PMID: 36228995)
Clin Imaging. 2013 Jan-Feb;37(1):104-10. (PMID: 23206615)
Radiology. 2019 Oct;293(1):4-14. (PMID: 31453768)
Adv Mater. 2024 Nov;36(44):e2407235. (PMID: 39264011)
Chin J Cancer Res. 2018 Oct;30(5):553-563. (PMID: 30510367)
J Control Release. 2019 Sep 10;309:1-10. (PMID: 31326463)
Radiology. 2022 Aug;304(2):483-484. (PMID: 35503022)
Langmuir. 2019 Aug 6;35(31):10087-10096. (PMID: 31033294)
Biomaterials. 2020 Nov;258:120297. (PMID: 32818824)
Chem Biol Interact. 2020 Feb 25;318:108973. (PMID: 32035862)
Med Phys. 2013 Jul;40(7):072902. (PMID: 23822453)
Semin Thromb Hemost. 2020 Jul;46(5):545-552. (PMID: 31096311)
Expert Opin Drug Deliv. 2022 Apr;19(4):421-433. (PMID: 35363586)
J Exp Clin Cancer Res. 2010 Dec 23;29:170. (PMID: 21176239)
Hepatology. 2014 Dec;60(6):2099-108. (PMID: 25164003)
Nat Rev Nephrol. 2021 Sep;17(9):575-590. (PMID: 34075241)
Echo Res Pract. 2025 Feb 21;12(1):4. (PMID: 39985014)
Medicine (Baltimore). 2019 Nov;98(44):e17745. (PMID: 31689827)
Int J Nanomedicine. 2021 Nov 04;16:7433-7447. (PMID: 34764649)
Ultrasound Med Biol. 2013 Nov;39(11):2158-65. (PMID: 23969165)
Nan Fang Yi Ke Da Xue Xue Bao. 2021 Aug 20;41(8):1220-1225. (PMID: 34549714)
ACS Biomater Sci Eng. 2022 Apr 11;8(4):1686-1695. (PMID: 35357814)
Clin Imaging. 2009 Nov-Dec;33(6):454-61. (PMID: 19857806)
Ultrasonics. 2012 Dec;52(8):1065-71. (PMID: 23021237)
Trends Genet. 2022 Jun;38(6):613-626. (PMID: 35303998)
J Funct Biomater. 2023 Jul 17;14(7):. (PMID: 37504868)
Ultraschall Med. 2020 Feb;41(1):29-35. (PMID: 31362328)
Int J Mol Sci. 2020 Dec 31;22(1):. (PMID: 33396561)
Proc Natl Acad Sci U S A. 2018 Jun 5;115(23):5839-5848. (PMID: 29802228)
Front Pharmacol. 2022 Jun 01;13:855495. (PMID: 35721213)
Adv Drug Deliv Rev. 2008 Jun 30;60(10):1103-16. (PMID: 18468716)
Cancers (Basel). 2019 Apr 24;11(4):. (PMID: 31022951)
Eur J Pharm Biopharm. 2019 Jun;139:224-231. (PMID: 30959180)
Int J Nanomedicine. 2021 May 10;16:3241-3254. (PMID: 34007176)
J Hepatol. 2023 Aug;79(2):516-537. (PMID: 36990226)
Radiology. 2021 Feb;298(2):450-457. (PMID: 33320067)
Theranostics. 2020 Sep 23;10(25):11690-11706. (PMID: 33052241)
Biomed Pharmacother. 2023 Apr;160:114322. (PMID: 36739766)
Am J Transl Res. 2019 Sep 15;11(9):5764-5775. (PMID: 31632546)
IEEE Trans Ultrason Ferroelectr Freq Control. 2021 Nov;68(11):3261-3269. (PMID: 34520353)
Cancer Imaging. 2023 Mar 23;23(1):29. (PMID: 36959681)
Expert Rev Med Devices. 2018 Nov;15(11):819-834. (PMID: 30350736)
Biomater Sci. 2021 Sep 7;9(17):5802-5811. (PMID: 34008615)
Adv Sci (Weinh). 2023 May;10(15):e2204890. (PMID: 37017572)
J Control Release. 2020 May 10;321:272-284. (PMID: 32004588)
Hepatobiliary Pancreat Dis Int. 2019 Feb;18(1):38-47. (PMID: 30243878)
Front Immunol. 2022 Jul 01;13:937344. (PMID: 35844515)
Adv Mater. 2024 Jan;36(3):e2306993. (PMID: 37851922)
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2018 Jul;10(4):e1502. (PMID: 29148219)
Mol Aspects Med. 2019 Feb;65:37-55. (PMID: 30213667)
Mol Ther Methods Clin Dev. 2019 Jul 26;14:275-284. (PMID: 31497618)
ACS Nano. 2023 Jan 10;17(1):263-274. (PMID: 36354372)
Invest Radiol. 2020 Nov;55(11):711-721. (PMID: 32569010)
J Control Release. 2018 Jul 10;281:19-28. (PMID: 29758233)
Ultrasound Med Biol. 2019 Feb;45(2):301-343. (PMID: 30527395)
Clin Res Hepatol Gastroenterol. 2013 Dec;37(6):602-7. (PMID: 24012221)
Gene Ther. 2013 Dec;20(12):1140-8. (PMID: 23966015)
Curr Opin Chem Biol. 2021 Aug;63:171-179. (PMID: 34102582)
Adv Mater. 2022 Sep;34(37):e2202625. (PMID: 35906003)
Nanomaterials (Basel). 2020 Sep 28;10(10):. (PMID: 32998422)
Exp Biol Med (Maywood). 2020 Aug;245(14):1200-1212. (PMID: 32567346)
Expert Opin Drug Deliv. 2006 Nov;3(6):713-26. (PMID: 17076594)
Sci Rep. 2020 Apr 20;10(1):6657. (PMID: 32313093)
Toxicol Appl Pharmacol. 2023 Sep 1;474:116605. (PMID: 37355104)
Eur J Radiol. 2017 Nov;96:65-73. (PMID: 29103478)
ACS Appl Mater Interfaces. 2019 Nov 13;11(45):41842-41852. (PMID: 31633326)
J Control Release. 2023 Jun;358:319-332. (PMID: 37149150)
Front Pharmacol. 2022 Jan 04;12:745693. (PMID: 35082664)
Hepatology. 2008 Jun;47(6):1955-63. (PMID: 18433021)
Int J Nanomedicine. 2022 Sep 07;17:3989-4008. (PMID: 36105615)
Biomater Sci. 2024 Dec 17;13(1):179-192. (PMID: 39506528)
Adv Drug Deliv Rev. 2008 Jun 30;60(10):1153-66. (PMID: 18486268)
Theranostics. 2021 Jan 1;11(1):79-92. (PMID: 33391462)
Adv Colloid Interface Sci. 2021 Aug;294:102407. (PMID: 34120037)
Pflugers Arch. 2021 Feb;473(2):139-150. (PMID: 33141239)
J Control Release. 2020 Oct 10;326:75-90. (PMID: 32554041)
Anal Cell Pathol (Amst). 2021 Apr 17;2021:8837950. (PMID: 33959473)
Ultrasound Med Biol. 2020 Oct;46(10):2579-2604. (PMID: 32713788)
Eur Radiol. 2009 Mar;19(3):651-63. (PMID: 18815790)
Front Pharmacol. 2021 Oct 19;12:768436. (PMID: 34737709)
Theranostics. 2023 Jun 4;13(10):3402-3418. (PMID: 37351172)
Adv Sci (Weinh). 2021 Feb 10;8(7):2002567. (PMID: 33854878)
Radiology. 2022 Apr;303(1):11-25. (PMID: 35191740)
Ultrasound Med Biol. 2020 Jun;46(6):1326-1343. (PMID: 32169397)
Acta Biomater. 2020 May;108:313-325. (PMID: 32268236)
J Control Release. 2016 Dec 10;243:172-181. (PMID: 27744037)
Adv Healthc Mater. 2021 Dec;10(23):e2101628. (PMID: 34514740)
J Nanobiotechnology. 2025 Feb 6;23(1):84. (PMID: 39910556)
Stem Cell Res Ther. 2020 Apr 3;11(1):145. (PMID: 32245503)
Eur Radiol. 2023 Feb;33(2):988-995. (PMID: 36205769)
Mol Pharm. 2020 Feb 3;17(2):541-553. (PMID: 31876426)
Endosc Ultrasound. 2024 Sep-Oct;13(5):306-311. (PMID: 40386454)
Adv Drug Deliv Rev. 2014 Jun;72:28-48. (PMID: 24667643)
J Hepatol. 2019 Jul;71(1):212-221. (PMID: 30871980)
J Control Release. 2015 Jul 10;209:139-49. (PMID: 25913365)
Stem Cells Dev. 2010 Aug;19(8):1143-51. (PMID: 20021260)
J Clin Invest. 2017 Jan 3;127(1):55-64. (PMID: 28045404)
Contributed Indexing: Keywords: Ultrasound-targeted microbubble destruction (UTMD); contrast-enhanced ultrasound; liver diseases; molecular imaging; targeted drug delivery; theranostics
Substance Nomenclature: 0 (Contrast Media)
Entry Date(s): Date Created: 20250807 Date Completed: 20250807 Latest Revision: 20250810
Update Code: 20250811
PubMed Central ID: PMC12333039
DOI: 10.1080/10717544.2025.2541656
PMID: 40771132
Databáza: MEDLINE
Popis
Abstrakt:Liver diseases, particularly chronic conditions leading to cirrhosis and hepatocellular carcinoma, represent a major global health burden with high mortality rates, necessitating innovative diagnostic and therapeutic approaches. Ultrasound-targeted microbubble destruction (UTMD) technology has emerged as a promising theranostic platform, combining enhanced contrast imaging with targeted drug/gene delivery capabilities. When activated by ultrasound, these microbubbles exhibit unique biophysical behaviors that significantly improve drug penetration, tissue perfusion, and site-specific delivery. This review comprehensively examines recent advancements in UTMD-based strategies for liver disease management, including microbubble design and imaging-targeted functionalization, and mechanisms of ultrasound-enhanced drug delivery, especially emerging theranostic applications. We further discuss the underlying biophysical principles governing microbubble-ultrasound interactions and their translational potential, providing insights for developing next-generation precision medicine approaches for hepatic disorders.
ISSN:1521-0464
DOI:10.1080/10717544.2025.2541656